# Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

> **NCT04966741** · PHASE3 · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Bardet-Biedl Syndrome
- POMC Deficiency Obesity
- PCSK1 Deficiency Obesity
- LEPR Deficiency Obesity

## Interventions

- **DRUG:** Setmelanotide

## Key facts

- **NCT ID:** NCT04966741
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-08
- **Primary completion:** 2023-09-18
- **Final completion:** 2024-11-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04966741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04966741, "Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04966741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*